AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Melanoma: Role of Molecular Diagnostics

Description

The discussion focuses on the role of molecular diagnostics in melanoma, particularly addressing the challenges and inconsistencies in diagnosing melanocytic lesions. The speaker outlines the limitations of traditional histopathological techniques, highlighting the need for molecular testing to improve diagnostic accuracy, especially in ambiguous cases. Various molecular tests, such as comparative genomic hybridization (CGH), fluorescence in situ hybridization (FISH), and gene expression profiling (GEP), are presented as tools that can help differentiate between benign nevi and malignant melanomas. The conversation emphasizes the importance of concordance among pathologists when diagnosing clear cases versus ambiguous lesions. Additionally, the speaker mentions that these molecular tests can sometimes validate diagnoses but still struggle with the 'gold standard' issue, as their results rely on histopathological benchmarks that can be subjective. The discussion raises the potential of molecular testing to reduce overdiagnosis but cautions that simply confirming malignancy does not always reflect the indolent nature of certain lesions. The conclusion advocates for an increased diagnostic threshold among dermatologists and pathologists to combat overdiagnosis and suggests that molecular tests, while beneficial, should be interpreted within a broader clinical context.

View more

Conclusions

  • High intra- and interobserver concordance exists for clear benign or malignant cases, but lower consensus is seen in ambiguous lesions.
  • Pathologists often struggle with ambiguous melanocytic lesions, leading to lower diagnostic concordance rates.
  • Molecular testing can assist in differentiating between benign nevi and malignant melanoma, particularly in uncertain cases.
  • The efficacy of molecular tests varies, with studies showing a sensitivity of 95% for aCGH in clear cases but lower for ambiguous lesions.
  • All molecular tests are compared against histopathologic diagnoses, which presents a 'gold standard' problem.
  • Long-term outcomes for ambiguous lesions remain under-studied, limiting validation of molecular tests.
  • The treatment of ambiguous lesions complicates understanding their natural progression if left untreated.
  • Molecular tests such as GEP and PRAME show promise in aiding diagnosis but are not always conclusive.
  • Increasing diagnostic thresholds may help reduce the rate of overdiagnosis of melanoma.
  • Collaboration between dermatologists and dermatopathologists is crucial to improve diagnostic accuracy and minimize unnecessary interventions.
  • Elmore JG, Barnhill RL, Elder DE, Longton GM, Pepe MS, Reisch LM, Carney PA, Titus LJ, Nelson HD, Onega T, Tosteson ANA, Weinstock MA, Knezevich SR, Piepkorn MW. Pathologists' diagnosis of invasive melanoma and melanocytic proliferations: observer accuracy and reproducibility study. BMJ. 2017 Jun 28;357:j2813. doi: 10.1136/bmj.j2813. Erratum in: BMJ. 2017 Aug 8;358:j3798. PMID: 28659278; PMCID: PMC5485913.
  • Barnhill RL, Elder DE, Piepkorn MW, Knezevich SR, Reisch LM, Eguchi MM, Bastian BC, Blokx W, Bosenberg M, Busam KJ, Carr R, Cochran A, Cook MG, Duncan LM, Elenitsas R, de la Fouchardière A, Gerami P, Johansson I, Ko J, Landman G, Lazar AJ, Lowe L, Massi D, Messina J, Mihic-Probst D, Parker DC, Schmidt B, Shea CR, Scolyer RA, Tetzlaff M, Xu X, Yeh I, Zembowicz A, Elmore JG. Revision of the Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis Classification Schema for Melanocytic Lesi
  • Emanuel PO, Andea AA, Vidal CI, Missall TA, Novoa RA, Bohlke AK, Hughes SR, Hurley MY, Kim J. Evidence behind the use of molecular tests in melanocytic lesions and practice patterns of these tests by dermatopathologists. J Cutan Pathol. 2018 Nov;45(11):839-846. doi: 10.1111/cup.13327. Epub 2018 Aug 22. PMID: 30039879.
  • Bastian BC, Olshen AB, LeBoit PE, Pinkel D. Classifying melanocytic tumors based on DNA copy number changes. Am J Pathol. 2003 Nov;163(5):1765-70. doi: 10.1016/S0002-9440(10)63536-5. PMID: 14578177; PMCID: PMC1892437.
  • Busam KJ. Molecular pathology of melanocytic tumors. Semin Diagn Pathol. 2013 Nov;30(4):362-74. doi: 10.1053/j.semdp.2013.11.002. Epub 2013 Nov 12. PMID: 24342290.
  • Miedema J, Andea AA. Through the looking glass and what you find there: making sense of comparative genomic hybridization and fluorescence in situ hybridization for melanoma diagnosis. Mod Pathol. 2020 Jul;33(7):1318-1330. doi: 10.1038/s41379-020-0490-7. Epub 2020 Feb 17. PMID: 32066861.
  • Mesbah Ardakani N, Thomas C, Robinson C, Mina K, Harvey NT, Amanuel B, Wood BA. Detection of copy number variations in melanocytic lesions utilising array based comparative genomic hybridisation. Pathology. 2017 Apr;49(3):285-291. doi: 10.1016/j.pathol.2016.11.008. Epub 2017 Mar 6. PMID: 28274670.
  • Carter MD, Durham AB, Miedema JR, Harms PW, Chan MP, Patel RM, Lowe L, Fullen DR, Hristov AC, Wang M, Andea AA. Molecular testing of borderline cutaneous melanocytic lesions: SNP array is more sensitive and specific than FISH. Hum Pathol. 2019 Apr;86:115-123. doi: 10.1016/j.humpath.2018.12.002. Epub 2018 Dec 18. PMID: 30576704.
  • Reimann JDR, Salim S, Velazquez EF, Wang L, Williams KM, Flejter WL, Brooke L, Sunder S, Busam KJ. Comparison of melanoma gene expression score with histopathology, fluorescence in situ hybridization, and SNP array for the classification of melanocytic neoplasms. Mod Pathol. 2018 Nov;31(11):1733-1743. doi: 10.1038/s41379-018-0087-6. Epub 2018 Jun 28. PMID: 29955141; PMCID: PMC6631355.
  • Alomari AK, Miedema JR, Carter MD, Harms PW, Lowe L, Durham AB, Fullen DR, Patel RM, Hristov AC, Chan MP, Wang M, Andea AA. DNA copy number changes correlate with clinical behavior in melanocytic neoplasms: proposal of an algorithmic approach. Mod Pathol. 2020 Jul;33(7):1307-1317. doi: 10.1038/s41379-020-0499-y. Epub 2020 Feb 17. PMID: 32066860.
  • Lezcano C, Jungbluth AA, Busam KJ. Immunohistochemistry for PRAME in Dermatopathology. Am J Dermatopathol. 2023 Nov 1;45(11):733-747. doi: 10.1097/DAD.0000000000002440. PMID: 37856737; PMCID: PMC10593485.
  • Bahmad HF, Oh KS, Alexis J. Potential diagnostic utility of PRAME and p16 immunohistochemistry in melanocytic nevi and malignant melanoma. J Cutan Pathol. 2023 Aug;50(8):763-772. doi: 10.1111/cup.14438. Epub 2023 Apr 27. PMID: 37114299.
  • Boutko A, Asadbeigi S, Roth A, Lampley N, Olivares S, Dittmann D, Jennings L, Gerami P. TERT Promoter Mutational Analysis as an Ancillary Diagnostic Tool for Diagnostically Challenging Melanocytic Neoplasms. Am J Dermatopathol. 2023 May 1;45(5):289-299. doi: 10.1097/DAD.0000000000002366. Epub 2023 Feb 17. PMID: 36898007.
  • Bitterman A. Molecular testing to differentiate melanoma from benign nevi: the gold standard limitation. J Am Acad Dermatol. 2016 Oct;75(4):849-850. doi: 10.1016/j.jaad.2016.06.038. PMID: 27646748.